Literature DB >> 25534939

Pathogenic Leptospira species acquire factor H and vitronectin via the surface protein LcpA.

Ludmila Bezerra da Silva1, Lidia Dos Santos Miragaia1, Leandro Carvalho Dantas Breda2, Cecilia Mari Abe3, Mariana Costa Braga Schmidt4, Ana Maria Moro4, Denize Monaris1, Jonas Nascimento Conde5, Mihály Józsi6, Lourdes Isaac2, Patrícia Antônia Estima Abreu1, Angela Silva Barbosa7.   

Abstract

Upon infection, pathogenic Leptospira species bind several complement regulators in order to overcome host innate immunity. We previously characterized a 20-kDa leptospiral surface protein which interacts with C4b binding protein (C4BP): leptospiral complement regulator-acquiring protein A (LcpA). Here we show that LcpA also interacts with human factor H (FH), which remains functionally active once bound to the protein. Antibodies directed against short consensus repeat 20 (SCR20) inhibited binding of FH to LcpA by approximately 90%, thus confirming that this particular domain is involved in the interaction. We have also shown for the first time that leptospires bind human vitronectin and that the interaction is mediated by LcpA. Coincubation with heparin blocked LcpA-vitronectin interaction in a dose-dependent manner, strongly suggesting that binding may occur through the heparin binding domains of vitronectin. LcpA also bound to the terminal pathway component C9 and inhibited Zn(2+)-induced polymerization and membrane attack complex (MAC) formation. Competitive binding assays indicated that LcpA interacts with C4BP, FH, and vitronectin through distinct sites. Taken together, our findings indicate that LcpA may play a role in leptospiral immune evasion.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25534939      PMCID: PMC4333444          DOI: 10.1128/IAI.02844-14

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

1.  ANTILEPTOSPIRAL ACTIVITY OF NORMAL SERUM.

Authors:  R C JOHNSON; L H MUSCHEL
Journal:  J Bacteriol       Date:  1965-06       Impact factor: 3.490

2.  Immune evasion by pathogenic Leptospira strains: the secretion of proteases that directly cleave complement proteins.

Authors:  Tatiana Rodrigues Fraga; Daniella Dos Santos Courrol; Mónica Marcela Castiblanco-Valencia; Izaura Yoshico Hirata; Sílvio Arruda Vasconcellos; Luiz Juliano; Angela Silva Barbosa; Lourdes Isaac
Journal:  J Infect Dis       Date:  2013-10-26       Impact factor: 5.226

3.  Quantitation of vitronectin in serum: evaluation of its usefulness in routine clinical practice.

Authors:  N A Boyd; A R Bradwell; R A Thompson
Journal:  J Clin Pathol       Date:  1993-11       Impact factor: 3.411

Review 4.  Role of vitronectin and its receptors in haemostasis and vascular remodeling.

Authors:  K T Preissner; D Seiffert
Journal:  Thromb Res       Date:  1998-01-01       Impact factor: 3.944

5.  Serum-resistant strains of Borrelia burgdorferi evade complement-mediated killing by expressing a CD59-like complement inhibitory molecule.

Authors:  Mario Pausa; Valentina Pellis; Marina Cinco; Piero G Giulianini; Gianni Presani; Sandra Perticarari; Rossella Murgia; Francesco Tedesco
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

6.  Whole-genome analysis of Leptospira interrogans to identify potential vaccine candidates against leptospirosis.

Authors:  Marcia Gamberini; Ricardo M Gómez; Marina V Atzingen; Elizabeth A L Martins; Silvio A Vasconcellos; Eliete C Romero; Luciana C C Leite; Paulo L Ho; Ana L T O Nascimento
Journal:  FEMS Microbiol Lett       Date:  2005-03-15       Impact factor: 2.742

7.  Multimeric vitronectin. Identification and characterization of conformation-dependent self-association of the adhesive protein.

Authors:  A Stockmann; S Hess; P Declerck; R Timpl; K T Preissner
Journal:  J Biol Chem       Date:  1993-10-25       Impact factor: 5.157

8.  Control of the amplification convertase of complement by the plasma protein beta1H.

Authors:  J M Weiler; M R Daha; K F Austen; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

9.  Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution.

Authors:  M K Pangburn; R D Schreiber; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307

10.  Modulation of the alternative complement pathways by beta 1 H globulin.

Authors:  K Whaley; S Ruddy
Journal:  J Exp Med       Date:  1976-11-02       Impact factor: 14.307

View more
  22 in total

1.  Role of Supramolecule ErpY-Like Lipoprotein of Leptospira in Thrombin-Catalyzed Fibrin Clot Inhibition and Binding to Complement Factors H and I, and Its Diagnostic Potential.

Authors:  Karukriti Kaushik Ghosh; Aman Prakash; Anusua Dhara; Md Saddam Hussain; Prateek Shrivastav; Pankaj Kumar; Vinayagamurthy Balamurugan; Manish Kumar
Journal:  Infect Immun       Date:  2019-11-18       Impact factor: 3.441

2.  Acquisition of negative complement regulators by the saprophyte Leptospira biflexa expressing LigA or LigB confers enhanced survival in human serum.

Authors:  Mónica M Castiblanco-Valencia; Tatiana R Fraga; Leandro C D Breda; Sílvio A Vasconcellos; Cláudio P Figueira; Mathieu Picardeau; Elsio Wunder; Albert I Ko; Angela S Barbosa; Lourdes Isaac
Journal:  Immunol Lett       Date:  2016-03-11       Impact factor: 3.685

3.  Inhibition of the Membrane Attack Complex by Dengue Virus NS1 through Interaction with Vitronectin and Terminal Complement Proteins.

Authors:  Jonas Nascimento Conde; Emiliana Mandarano da Silva; Diego Allonso; Diego Rodrigues Coelho; Iamara da Silva Andrade; Luciano Neves de Medeiros; Joice Lima Menezes; Angela Silva Barbosa; Ronaldo Mohana-Borges
Journal:  J Virol       Date:  2016-10-14       Impact factor: 5.103

4.  Fine Mapping of the Interaction between C4b-Binding Protein and Outer Membrane Proteins LigA and LigB of Pathogenic Leptospira interrogans.

Authors:  Leandro C D Breda; Ching-Lin Hsieh; Mónica M Castiblanco Valencia; Ludmila B da Silva; Angela S Barbosa; Anna M Blom; Yung-Fu Chang; Chang Yung-Fu; Lourdes Isaac
Journal:  PLoS Negl Trop Dis       Date:  2015-10-30

Review 5.  Complement Evasion by Pathogenic Leptospira.

Authors:  Tatiana Rodrigues Fraga; Lourdes Isaac; Angela Silva Barbosa
Journal:  Front Immunol       Date:  2016-12-21       Impact factor: 7.561

6.  Role of Murine Complement Component C5 in Acute in Vivo Infection by Pathogenic Leptospira interrogans.

Authors:  Íris A de Castro; Lorena Bavia; Tatiana R Fraga; Mariane T Amano; Leandro C D Breda; Adriana P Granados-Martinez; Ana M G da Silva; Silvio A Vasconcellos; Lourdes Isaac
Journal:  Front Cell Infect Microbiol       Date:  2018-03-08       Impact factor: 5.293

7.  Pathogenic Leptospira Secreted Proteases Target the Membrane Attack Complex: A Potential Role for Thermolysin in Complement Inhibition.

Authors:  Thais A Amamura; Tatiana R Fraga; Sílvio A Vasconcellos; Angela S Barbosa; Lourdes Isaac
Journal:  Front Microbiol       Date:  2017-05-30       Impact factor: 5.640

8.  The Rickettsia conorii Adr1 Interacts with the C-Terminus of Human Vitronectin in a Salt-Sensitive Manner.

Authors:  Abigail I Fish; Sean P Riley; Birendra Singh; Kristian Riesbeck; Juan J Martinez
Journal:  Front Cell Infect Microbiol       Date:  2017-03-01       Impact factor: 5.293

9.  A Novel Leptospira interrogans Protein LIC13086 Inhibits Fibrin Clot Formation and Interacts With Host Components.

Authors:  Felipe José Passalia; Marcos Bryan Heinemann; Mônica Larucci Vieira; Ana Lucia T O Nascimento
Journal:  Front Cell Infect Microbiol       Date:  2021-07-01       Impact factor: 5.293

10.  Conserved Patterns of Microbial Immune Escape: Pathogenic Microbes of Diverse Origin Target the Human Terminal Complement Inhibitor Vitronectin via a Single Common Motif.

Authors:  Teresia Hallström; Birendra Singh; Peter Kraiczy; Sven Hammerschmidt; Christine Skerka; Peter F Zipfel; Kristian Riesbeck
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.